Retinoblastoma protein expressed in human non-Hodgkin's lymphoma cells generates resistance against radiation-induced apoptosis

Ishii, Hideshi; Igarashi, Tadahiko; Nakano, Tomoko; Mori, Masataka; Ohyama, Harumi; Miyamoto, Tadaaki; Saitō, Yasushi; Oh, Hakumei

doi:10.1002/(sici)1096-8652(199705)55:1<46::aid-ajh9>3.0.co;2-3

Cited by 12 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No correlation was found with progression-free survival and chance to achieve a complete response to therapy (Sanchez et al, 1998), although a predictive role of pRb for response to radiation has been suggested (Ishii et al, 1997).…”

Section: Hematological Malignanciesmentioning

confidence: 99%

RB family members as predictive and prognostic factors in human cancer

2006

View full text Add to dashboard Cite

Section: Hematological Malignanciesmentioning

confidence: 99%

RB family members as predictive and prognostic factors in human cancer

2006

View full text Add to dashboard Cite

“…Several observations from RB1 knockdown and overexpression studies confirmed the antiapoptotic role of RB1 also in response to different apoptotic stimuli. In particular, RB1 knockdown has been shown to enhance the sensitivity to cell death induced by different anticancer agents, such as DNA-damaging and microtubule interfering agents, in cells from several cancer types, including lymphoma, breast, lung, and prostate cancer, and glioblastoma [ 46 – 50 ]. Similarly, RB1 ablation in mouse embryonic and adult fibroblasts increased the sensitivity to chemotherapy-induced cell death [ 51 – 53 ].…”

Section: Introductionmentioning

confidence: 99%

RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy

et al. 2015

View full text Add to dashboard Cite

Inactivation of the retinoblastoma (RB1) tumor suppressor is one of the most frequent and early recognized molecular hallmarks of cancer. RB1, although mainly studied for its role in the regulation of cell cycle, emerged as a key regulator of many biological processes. Among these, RB1 has been implicated in the regulation of apoptosis, the alteration of which underlies both cancer development and resistance to therapy. RB1 role in apoptosis, however, is still controversial because, depending on the context, the apoptotic cues, and its own status, RB1 can act either by inhibiting or promoting apoptosis. Moreover, the mechanisms whereby RB1 controls both proliferation and apoptosis in a coordinated manner are only now beginning to be unraveled. Here, by reviewing the main studies assessing the effect of RB1 status and modulation on these processes, we provide an overview of the possible underlying molecular mechanisms whereby RB1, and its family members, dictate cell fate in various contexts. We also describe the current antitumoral strategies aimed at the use of RB1 as predictive, prognostic and therapeutic target in cancer. A thorough understanding of RB1 function in controlling cell fate determination is crucial for a successful translation of RB1 status assessment in the clinical setting.

show abstract

“…Paradoxically, pRB inhibits apoptosis triggered by a number of different agents (Haas‐Kogan et al, 1995; Haupt et al, 1995; McConkey et al, 1996; Ishii et al, 1997; Wang et al, 1997). In contrast to its role as a tumor suppressor gene, the ability to suppress apoptosis is predicted to be oncogenic.…”

Section: Rb1 Functionmentioning

confidence: 99%

How the other half lives, the amino‐terminal domain of the retinoblastoma tumor suppressor protein

Goodrich

2003

Journal Cellular Physiology

View full text Add to dashboard Cite

The retinoblastoma tumor suppressor gene (RB1) is currently the only known gene whose mutation is necessary and sufficient for the development of a human cancer. Mutation or deregulation of RB1 is observed so frequently in other tumor types that compromising RB1 function may be a prerequisite for malignant transformation. Identifying the molecular mechanisms that provide the basis for RB1-mediated tumor suppression has become an important goal in the quest to understand and treat cancer. The lion's share of research on these mechanisms has focused on the carboxy-terminal half of the RB1 encoded protein (pRB). This focus is with good reason since this part of the protein, now called the ''large pocket,'' is required for most of its known activities identified in vitro and in vivo. Large pocket mediated mechanisms alone, however, cannot account for all observed properties of pRB. The thesis presented here is that the relatively uncharacterized amino-terminal half of the protein makes important contributions to pRB-mediated tumor suppression. The goals of this review are to summarize evidence indicating that an aminoterminal structural domain is important for pRB function and to suggest a general hypothesis as to how this domain can be integrated with current models of pRB function.

show abstract

Retinoblastoma protein expressed in human non-Hodgkin's lymphoma cells generates resistance against radiation-induced apoptosis

Cited by 12 publications

References 8 publications

RB family members as predictive and prognostic factors in human cancer

RB family members as predictive and prognostic factors in human cancer

RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy

How the other half lives, the amino‐terminal domain of the retinoblastoma tumor suppressor protein

Contact Info

Product

Resources

About